The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

NCT01536665 · Completed

Last updated 2026-05-28

This clinical trial tests whether adding the medication liraglutide to insulin treatment affects the body's glucagon response during low blood sugar in adults with type 1 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 45 people

Who can join Ages 18–64 · all sexes

Timeline Started 2012-02 · est. completion 2012-08

Where 1 site · Austria

What this study is testing ClinicalTrials.gov NCT01536665 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate if liraglutide adjunct to insulin treatment changes the glucagon response during hypoglycaemia in subjects with type 1 diabetes compared with conventional insulin treatment after 4 weeks' treatment with liraglutide or placebo. Subjects will initially be randomised to one of the three dose groups, and subsequently randomly allocated to one of two treatment sequences (liraglutide/placebo or placebo/liraglutide).

Treatments tested

liraglutide Drug

Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
placebo Drug

Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.

Main thing measured	Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) )
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 1
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01536665 ↗